Product logins

Find logins to all Clarivate products below.


: Oncology

Here you will find relevant articles and insight into all Clarivate related products and news.

These six radioligand therapy companies to watch are ushering in a new era of precision oncology These six radioligand therapy companies to watch are ushering in a new era of precision oncology
Blog June 18, 2025
These six radioligand therapy companies to watch are ushering in a new era of precision oncology
Biopharma Clinical research Market Access
The role of artificial intelligence or machine learning in conducting systematic literature reviews now and in future The role of artificial intelligence or machine learning in conducting systematic literature reviews now and in future
Blog June 21, 2024
The role of artificial intelligence or machine learning in conducting systematic literature reviews now and in future
Clinical research Clinical trials corporate
These seven ADC makers are developing therapies that show promise for hard-to-treat cancers These seven ADC makers are developing therapies that show promise for hard-to-treat cancers
Blog June 17, 2024
These seven ADC makers are developing therapies that show promise for hard-to-treat cancers
Clinical research Early drug development research Oncology
Indication Expansion: Pioneering new uses for existing cancer drugs Indication Expansion: Pioneering new uses for existing cancer drugs
Blog May 31, 2024
Indication Expansion: Pioneering new uses for existing cancer drugs
Clinical research Clinical trials Consulting Resource Center
Pharma is placing bigger bets on fewer, more strategic assets and platforms Pharma is placing bigger bets on fewer, more strategic assets and platforms
Blog May 8, 2024
Pharma is placing bigger bets on fewer, more strategic assets and platforms
Oncology Pharma Portfolio strategy
What sets the Drugs to Watch in 2024 apart What sets the Drugs to Watch in 2024 apart
Blog January 8, 2024
What sets the Drugs to Watch in 2024 apart
Clinical trials Mainland China Oncology
What to watch in the life sciences in 2024 What to watch in the life sciences in 2024
Blog December 14, 2023
What to watch in the life sciences in 2024
Oncology Pharma Portfolio strategy
Five points on CMS's first ten picks for price negotiations Five points on CMS's first ten picks for price negotiations
Blog October 25, 2023
Five points on CMS's first ten picks for price negotiations
Health policy Inflation Reduction Act IRA

Oncology

Blog March 30, 2017
Outcomes-Based Contracting Gain Steam
Blog March 30, 2017
ACC.17: a roller coaster of results
Blog March 23, 2017
Device deals climb with a focus on cancer, cardiovascular markets
Blog December 1, 2016
HIEs diversify, grow in 2016
Blog November 18, 2016
Repeal, Replace and Paul Ryan: How the Republicans Plan to Reform Healthcare Reform
Blog November 16, 2016
Election 2016: Did pharma win or lose?
Blog August 9, 2016
Opdivo falls short in the first-line CheckMate-026 NSCLC trial – what will the repercussions be on its commercial prospects?
Blog June 29, 2016
The What and Why of Budget Impact Models
Blog June 15, 2016
Paying for Performance: EFPIA’s Catch-22 for European Drug Pricing
Blog May 31, 2016
Russia: Capricious or Compulsory Licensing?